A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Fourteen Day Treatment With Lansoprazole 15 mg or 30 mg Once a Day in Frequent Nighttime Heartburn

Trial Profile

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Fourteen Day Treatment With Lansoprazole 15 mg or 30 mg Once a Day in Frequent Nighttime Heartburn

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2010

At a glance

  • Drugs Lansoprazole (Primary)
  • Indications Heartburn
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Sep 2009 Results have been reported in Alimentary Pharmacology and Therapeutics.
    • 04 Jun 2009 The primary endpoint 'Night-time-symptom-free-days' has been Met according to the poster presented at Digestive Disease Week 2009, 30 May 2009.
    • 04 Jun 2009 Results published as an abstract in the proceedings of Digestive Disease Week 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top